Reichert Janice M, Beck Alain, Lugovskoy Alexey A, Wurch Thierry, Coats Steven, Brezski Randall J
Reichert Biotechnology Consulting; Framingham, MA USA.
Centre d'Immunologie Pierre Fabre; Saint Julien en Genevois, France.
MAbs. 2014 Mar-Apr;6(2):309-26. doi: 10.4161/mabs.27903. Epub 2014 Jan 17.
The annual European Antibody Congress (EAC) has traditionally been the key event for updates on critical scientific advances in the antibody field, and 2013 was no exception. Organized by Terrapinn, the well-attended meeting featured presentations on considerations for developing antibodies and antibody-like therapeutics, with separate tracks for antibody-drug conjugates, naked antibodies, and multispecific antibodies or protein scaffolds. The overall focus of the EAC was current approaches to enhance the functionality of therapeutic antibodies or other targeted proteins, with the ultimate goal being improvement of the safety and efficacy of the molecules as treatments for cancer, immune-mediated disorders and other diseases. Roundtable discussion sessions gave participants opportunities to engage in group discussions with industry leaders from companies such as Genmab, Glenmark Pharmaceuticals, MedImmune, Merrimack Pharmaceuticals, and Pierre Fabre. As the 2013 EAC was co-located with the World Biosimilar Congress, participants also received an update on European Medicines Agency guidelines and thoughts on the future direction and development of biosimilar antibodies in the European Union.
一年一度的欧洲抗体大会（EAC）向来是抗体领域关键科学进展最新情况的重要活动，2013年也不例外。该会议由特瑞平公司组织，参会者众多，会上展示了有关开发抗体及类抗体疗法的考量，设有抗体药物偶联物、裸抗体以及多特异性抗体或蛋白质支架等不同专题。欧洲抗体大会的总体重点是增强治疗性抗体或其他靶向蛋白功能的当前方法，最终目标是提高这些分子作为癌症、免疫介导疾病及其他疾病治疗手段的安全性和有效性。圆桌讨论环节让与会者有机会与来自Genmab、格兰马克制药、MedImmune、美礼联制药和皮尔法伯等公司的行业领袖进行小组讨论。由于2013年欧洲抗体大会与世界生物类似药大会同期举行，与会者还了解到了欧洲药品管理局的指南更新情况以及欧盟生物类似抗体未来发展方向的相关观点。
